NeoGenomics, Inc.
87.97xPrice / tangible book
Market cap
$2.26B
Tangible equity
$25.69M
Price / tangible book
87.97x
Price / book
2.70x
Return on equity
-12.9%
Return on assets
-7.9%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: NEO stock price vs MA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MA's multiple
Needs MA P/B.
Implied fair value · at NEO's multiple
Needs Book value / share.
Metric by metric
Snapshot Sep 8, 2026, 3:52 PM ET
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability lag
Asset efficiency lag
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: NEO FY 2025 (ended Dec 31, 2025) · MA FY 2025 (ended Dec 31, 2025).
Trendline
Nine fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / tangible book
Market cap
$2.26B
Tangible equity
$25.69M
Price / tangible book
87.97x
Price / book
2.70x
Return on equity
-12.9%
Return on assets
-7.9%
Efficiency ratio
—
Price / book
Market cap
—
Tangible equity
-$7.38B
Price / tangible book
—
Price / book
—
Return on equity
193.5%
Return on assets
27.6%
Efficiency ratio
—
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NeoGenomics, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Mastercard Incorporated · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.41x
2.46x
Net debt / EBITDA
Leverage against operating earnings
-4.48x
0.43x
Cash and equivalents
Liquid reserves on the balance sheet
$159.62M
$10.57B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
NEO vs LH
QUEST DIAGNOSTICS INC
NEO vs DGX
OPKO HEALTH, INC.
NEO vs OPK
Guardant Health, Inc.
NEO vs GH
Natera, Inc.
NEO vs NTRA
EXACT SCIENCES CORP
NEO vs EXAS
Visa Inc.
NEO vs V
American Express Company
NEO vs AXP
PayPal Holdings, Inc.
NEO vs PYPL
Discover Financial Services
NEO vs DFS
$341.86M
$19.00B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.